New Considerations for Diabetes in 2008
Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for
the issue, return to this Introduction page and click the "Take the Test" button. The Introduction
page will remain open after you open this issue.
You may need to re-size or close the issue in order
to see the Introduction page.
The development of type 2 diabetes mellitus (T2DM) involves three different mechanisms: insulin resistance, impaired insulin secretion, and excess production of glucose from the liver. Researchers are constantly seeking new drug therapy targets, and less invasive, more convenient routes of drug administration. As treatment for T2DM becomes more complicated and more clinical experience is gained with the drugs currently available, new issues and considerations inevitably arise. Whether these issues involve new insight into possible drug side effects, changes in glycemic treatment goals, or new thoughts involving our monitoring paradigms, it is in your best interest and your patients’ best interest to stay up-to-date.
This article summarizes 6 recent developments in the treatment of T2DM: the link between thiazolidinediones (e.g., Avandia®, Actos®) and bone fracture, the potential for heart attacks and heart failure associated with thiazolidinedione use, recent findings regarding tight glucose control and cardiovascular risk, the potential link between inhaled insulin (Exubera®) and lung cancer, use of the lipid-lowering drug colesevelam (WelCholTM) in patients with T2DM, and the potential benefits and drawbacks of self-monitoring of blood glucose (SMBG) in patients who are not using insulin. Each topic is accompanied by patient discussion points to aid you in your efforts to guide them through these recent developments.
Publication Date: 12/01/2008
Expiration Date: 12/01/2011
CE Credit: 1.5 (0.5 CEU)
Type of Activity: Knowledge-based
This program was developed by The Rx Consultant and published by Continuing Education Network, Inc.
The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and
is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased,
balanced information to health care practitioners.
Programs developed by The Rx Consultant are written by health care providers with expertise in the topic
area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure
that every program presents information that is current, accurate, relevant to "real world" health care
providers, and written in an easy reading, "plain English" style.
Joshua J. Neumiller, PharmD, CGP, FASCP, Assistant Professor, Department of Pharmacotherapy, College of Pharmacy, Washington State University/Elder Services, Spokane, WA; Brian J. Gates, PharmD, Clinical Associate Professor, Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA; Shelby Bottemiller, PharmD, Duvall Family Drugs, Duvall, WA; and R. Keith Campbell, RPh, MBA, CDE, FASHP, Distinguished Professor, Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, WA.
The authors reported no financial or personal relationship with any commercial interest producing, marketing, reselling,
or distributing a product or service that appears in this issue.
Guest Editorial Advisor
Lisa A. Kroon, PharmD, CDE
This accredited program is targeted to pharmacists and nurses.
Goals & Objectives
At the conclusion of this program, participants will be able to:
- Discuss recent developments concerning thiazolidinediones, including the increased risk of cardiovascular events and bone fracture. Discuss the clinical relevance of these findings and suggest appropriate patient counseling information.
- Discuss the results of recent studies that evaluated intensive T2DM treatment (ACCORD, ADVANCE, UKPDS). Describe the clinical implications for newly diagnosed patients and older patients with long-standing T2DM and high cardiovascular risk.
- Outline important considerations and counseling points for patients who were previously on inhaled insulin therapy.
- Describe the role of colesevelam in T2DM therapy.
- Provide practical guidance to patients regarding self-monitoring of blood glucose and appropriate A1C goals.
The Rx Consultant is a publication of Continuing Education Network, Inc.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a
provider of continuing pharmacy education.
Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.
ACPE Universal Activity Number: 428-0000-08-011-H01-P
Exam & Credit Statement Procedures
Upon successful completion of this program and the post test (70%), 1.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and
Editorial and Review Board
Chief Editor and CE Administrator
Terry M. Baker, PharmD
Tracy Farnen, PharmD
James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA
Richard Ron Finley, B.S. Pharm.,R.Ph.
Clinical Pharmacist (volunteer faculty)
University of California, San Francisco (UCSF) Memory and Aging Center
Lecturer (Emeritus) UCSF, Department of Clinical Pharmacy
Health Sciences Clinical Professor, UCSF School of Pharmacy
San Francisco, CA
Ray Dolby Brain Health Center, Sutter Health/CPMC
San Francisco, CA
Consult Pharmacist Aging and Adult Health Services
San Francisco Health Department
San Francisco, CA
Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System
Adjunct Clinical Professor
College of Pharmacy
Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Visiting Associate Professor and Lecturer
Samuel Merritt University
Pamela Mausner, MD
Helen Berlie, Pharm.D. CDE, BCACP
Clinical Assistant Professor, Pharmacy Practice
Wayne State University
Ambulatory Care Specialist - Diabetes
Health Centers Detroit Medical Group
Senior Editorial Advisor
Gerard Hatheway, PharmD, PhD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD
Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners
Meuleman, RN, C, MS
About the Rx Consultant
The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to
educate patients about drugs and manage drug therapy. The reader is responsible for confirming
the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.
Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.
Browser that supports TLS 1.1 + and PDF files.
This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.
Adobe Acrobat Reader is recommended, and is required for some browsers.
Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.
Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)